Pharmagreen Biotech Inc.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CHALF has a market cap of 441.8B. Regarding current trading prices, PHBI is priced at $0.00, while CHALF trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CHALF's P/E ratio is -4.75. In terms of profitability, PHBI's ROE is +0.09%, compared to CHALF's ROE of +0.00%. Regarding short-term risk, PHBI is less volatile compared to CHALF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, STMH has a market cap of 126.4B. Regarding current trading prices, PHBI is priced at $0.00, while STMH trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas STMH's P/E ratio is -0.05. In terms of profitability, PHBI's ROE is +0.09%, compared to STMH's ROE of -2.75%. Regarding short-term risk, PHBI is less volatile compared to STMH. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, THCBF has a market cap of 58.6B. Regarding current trading prices, PHBI is priced at $0.00, while THCBF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas THCBF's P/E ratio is -2.45. In terms of profitability, PHBI's ROE is +0.09%, compared to THCBF's ROE of +0.00%. Regarding short-term risk, PHBI is more volatile compared to THCBF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, MKKGY has a market cap of 57B. Regarding current trading prices, PHBI is priced at $0.00, while MKKGY trades at $26.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas MKKGY's P/E ratio is 17.79. In terms of profitability, PHBI's ROE is +0.09%, compared to MKKGY's ROE of +0.10%. Regarding short-term risk, PHBI is more volatile compared to MKKGY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, MKGAF has a market cap of 56.8B. Regarding current trading prices, PHBI is priced at $0.00, while MKGAF trades at $130.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas MKGAF's P/E ratio is 17.64. In terms of profitability, PHBI's ROE is +0.09%, compared to MKGAF's ROE of +0.10%. Regarding short-term risk, PHBI is more volatile compared to MKGAF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HLNCF has a market cap of 47B. Regarding current trading prices, PHBI is priced at $0.00, while HLNCF trades at $5.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HLNCF's P/E ratio is 24.81. In terms of profitability, PHBI's ROE is +0.09%, compared to HLNCF's ROE of +0.09%. Regarding short-term risk, PHBI is more volatile compared to HLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TKPHF has a market cap of 43.9B. Regarding current trading prices, PHBI is priced at $0.00, while TKPHF trades at $27.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TKPHF's P/E ratio is 59.38. In terms of profitability, PHBI's ROE is +0.09%, compared to TKPHF's ROE of +0.03%. Regarding short-term risk, PHBI is more volatile compared to TKPHF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, IPSEY has a market cap of 39.2B. Regarding current trading prices, PHBI is priced at $0.00, while IPSEY trades at $29.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas IPSEY's P/E ratio is 24.30. In terms of profitability, PHBI's ROE is +0.09%, compared to IPSEY's ROE of +0.17%. Regarding short-term risk, PHBI is more volatile compared to IPSEY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, EVRRF has a market cap of 25.7B. Regarding current trading prices, PHBI is priced at $0.00, while EVRRF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas EVRRF's P/E ratio is -2.40. In terms of profitability, PHBI's ROE is +0.09%, compared to EVRRF's ROE of +2.97%. Regarding short-term risk, PHBI is less volatile compared to EVRRF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SDZNY has a market cap of 22.3B. Regarding current trading prices, PHBI is priced at $0.00, while SDZNY trades at $51.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SDZNY's P/E ratio is -2594.00. In terms of profitability, PHBI's ROE is +0.09%, compared to SDZNY's ROE of +0.00%. Regarding short-term risk, PHBI is more volatile compared to SDZNY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TEVJF has a market cap of 20.4B. Regarding current trading prices, PHBI is priced at $0.00, while TEVJF trades at $17.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TEVJF's P/E ratio is -15.48. In terms of profitability, PHBI's ROE is +0.09%, compared to TEVJF's ROE of -0.21%. Regarding short-term risk, PHBI is less volatile compared to TEVJF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SRUTF has a market cap of 19.7B. Regarding current trading prices, PHBI is priced at $0.00, while SRUTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SRUTF's P/E ratio is -0.09. In terms of profitability, PHBI's ROE is +0.09%, compared to SRUTF's ROE of +18.75%. Regarding short-term risk, PHBI is less volatile compared to SRUTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, PHBI is priced at $0.00, while ESALY trades at $61.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ESALY's P/E ratio is 20.54. In terms of profitability, PHBI's ROE is +0.09%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, PHBI is more volatile compared to ESALY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SGIOY has a market cap of 14.6B. Regarding current trading prices, PHBI is priced at $0.00, while SGIOY trades at $8.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SGIOY's P/E ratio is 12.45. In terms of profitability, PHBI's ROE is +0.09%, compared to SGIOY's ROE of +0.08%. Regarding short-term risk, PHBI is more volatile compared to SGIOY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SGIOF has a market cap of 12.9B. Regarding current trading prices, PHBI is priced at $0.00, while SGIOF trades at $15.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SGIOF's P/E ratio is 10.86. In terms of profitability, PHBI's ROE is +0.09%, compared to SGIOF's ROE of +0.08%. Regarding short-term risk, PHBI is more volatile compared to SGIOF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, BIOVF has a market cap of 11B. Regarding current trading prices, PHBI is priced at $0.00, while BIOVF trades at $31.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas BIOVF's P/E ratio is 26.88. In terms of profitability, PHBI's ROE is +0.09%, compared to BIOVF's ROE of +0.10%. Regarding short-term risk, PHBI is less volatile compared to BIOVF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, IPSEF has a market cap of 10.4B. Regarding current trading prices, PHBI is priced at $0.00, while IPSEF trades at $125.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas IPSEF's P/E ratio is 25.74. In terms of profitability, PHBI's ROE is +0.09%, compared to IPSEF's ROE of +0.14%. Regarding short-term risk, PHBI is more volatile compared to IPSEF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, RDDTF has a market cap of 9.8B. Regarding current trading prices, PHBI is priced at $0.00, while RDDTF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas RDDTF's P/E ratio is -0.50. In terms of profitability, PHBI's ROE is +0.09%, compared to RDDTF's ROE of +0.00%. Regarding short-term risk, PHBI is less volatile compared to RDDTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NOBDF has a market cap of 8.5B. Regarding current trading prices, PHBI is priced at $0.00, while NOBDF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NOBDF's P/E ratio is N/A. In terms of profitability, PHBI's ROE is +0.09%, compared to NOBDF's ROE of -0.54%. Regarding short-term risk, PHBI is less volatile compared to NOBDF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ESAIY has a market cap of 7.9B. Regarding current trading prices, PHBI is priced at $0.00, while ESAIY trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ESAIY's P/E ratio is 25.04. In terms of profitability, PHBI's ROE is +0.09%, compared to ESAIY's ROE of +0.03%. Regarding short-term risk, PHBI is more volatile compared to ESAIY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SFOSF has a market cap of 7.8B. Regarding current trading prices, PHBI is priced at $0.00, while SFOSF trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SFOSF's P/E ratio is 13.03. In terms of profitability, PHBI's ROE is +0.09%, compared to SFOSF's ROE of +0.06%. Regarding short-term risk, PHBI is more volatile compared to SFOSF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ESALF has a market cap of 7.8B. Regarding current trading prices, PHBI is priced at $0.00, while ESALF trades at $27.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ESALF's P/E ratio is 24.34. In terms of profitability, PHBI's ROE is +0.09%, compared to ESALF's ROE of +0.03%. Regarding short-term risk, PHBI is more volatile compared to ESALF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HKMPY has a market cap of 6.3B. Regarding current trading prices, PHBI is priced at $0.00, while HKMPY trades at $56.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HKMPY's P/E ratio is 17.67. In terms of profitability, PHBI's ROE is +0.09%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, PHBI is more volatile compared to HKMPY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HKMPF has a market cap of 6.1B. Regarding current trading prices, PHBI is priced at $0.00, while HKMPF trades at $27.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HKMPF's P/E ratio is 17.22. In terms of profitability, PHBI's ROE is +0.09%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, PHBI is more volatile compared to HKMPF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, GZPHF has a market cap of 5.6B. Regarding current trading prices, PHBI is priced at $0.00, while GZPHF trades at $2.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas GZPHF's P/E ratio is 9.57. In terms of profitability, PHBI's ROE is +0.09%, compared to GZPHF's ROE of +0.07%. Regarding short-term risk, PHBI is less volatile compared to GZPHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HLBBF has a market cap of 4.5B. Regarding current trading prices, PHBI is priced at $0.00, while HLBBF trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HLBBF's P/E ratio is 11.71. In terms of profitability, PHBI's ROE is +0.09%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, PHBI is more volatile compared to HLBBF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LVZPF has a market cap of 3.8B. Regarding current trading prices, PHBI is priced at $0.00, while LVZPF trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LVZPF's P/E ratio is 11.43. In terms of profitability, PHBI's ROE is +0.09%, compared to LVZPF's ROE of +0.15%. Regarding short-term risk, PHBI is more volatile compared to LVZPF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HLUBF has a market cap of 3.6B. Regarding current trading prices, PHBI is priced at $0.00, while HLUBF trades at $3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HLUBF's P/E ratio is 7.55. In terms of profitability, PHBI's ROE is +0.09%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, PHBI is less volatile compared to HLUBF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, APNHF has a market cap of 3.2B. Regarding current trading prices, PHBI is priced at $0.00, while APNHF trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas APNHF's P/E ratio is 12.72. In terms of profitability, PHBI's ROE is +0.09%, compared to APNHF's ROE of +0.04%. Regarding short-term risk, PHBI is less volatile compared to APNHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, APNHY has a market cap of 3B. Regarding current trading prices, PHBI is priced at $0.00, while APNHY trades at $6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas APNHY's P/E ratio is 11.93. In terms of profitability, PHBI's ROE is +0.09%, compared to APNHY's ROE of +0.05%. Regarding short-term risk, PHBI is more volatile compared to APNHY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, PHBI is priced at $0.00, while INVVY trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas INVVY's P/E ratio is -62.42. In terms of profitability, PHBI's ROE is +0.09%, compared to INVVY's ROE of -0.01%. Regarding short-term risk, PHBI is more volatile compared to INVVY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, PHBI is priced at $0.00, while IZQVF trades at $20.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, PHBI's ROE is +0.09%, compared to IZQVF's ROE of -0.01%. Regarding short-term risk, PHBI is more volatile compared to IZQVF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, WIBFF has a market cap of 2.9B. Regarding current trading prices, PHBI is priced at $0.00, while WIBFF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas WIBFF's P/E ratio is -0.01. In terms of profitability, PHBI's ROE is +0.09%, compared to WIBFF's ROE of +0.00%. Regarding short-term risk, PHBI is less volatile compared to WIBFF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HYPMY has a market cap of 2.8B. Regarding current trading prices, PHBI is priced at $0.00, while HYPMY trades at $4.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HYPMY's P/E ratio is 19.48. In terms of profitability, PHBI's ROE is +0.09%, compared to HYPMY's ROE of +0.07%. Regarding short-term risk, PHBI is more volatile compared to HYPMY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HMDCF has a market cap of 2.8B. Regarding current trading prices, PHBI is priced at $0.00, while HMDCF trades at $3.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HMDCF's P/E ratio is -64.10. In terms of profitability, PHBI's ROE is +0.09%, compared to HMDCF's ROE of -0.01%. Regarding short-term risk, PHBI is less volatile compared to HMDCF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, DNPUF has a market cap of 2.6B. Regarding current trading prices, PHBI is priced at $0.00, while DNPUF trades at $6.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas DNPUF's P/E ratio is 15.55. In terms of profitability, PHBI's ROE is +0.09%, compared to DNPUF's ROE of -1.05%. Regarding short-term risk, PHBI is less volatile compared to DNPUF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ULIHF has a market cap of 2.5B. Regarding current trading prices, PHBI is priced at $0.00, while ULIHF trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ULIHF's P/E ratio is 7.00. In terms of profitability, PHBI's ROE is +0.09%, compared to ULIHF's ROE of +0.21%. Regarding short-term risk, PHBI is more volatile compared to ULIHF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CHSYF has a market cap of 2.2B. Regarding current trading prices, PHBI is priced at $0.00, while CHSYF trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CHSYF's P/E ratio is 6.65. In terms of profitability, PHBI's ROE is +0.09%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, PHBI is more volatile compared to CHSYF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TSMRF has a market cap of 2.1B. Regarding current trading prices, PHBI is priced at $0.00, while TSMRF trades at $28.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TSMRF's P/E ratio is 13.03. In terms of profitability, PHBI's ROE is +0.09%, compared to TSMRF's ROE of +0.07%. Regarding short-term risk, PHBI is more volatile compared to TSMRF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, PHBI is priced at $0.00, while DMPHF trades at $39.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas DMPHF's P/E ratio is 18.06. In terms of profitability, PHBI's ROE is +0.09%, compared to DMPHF's ROE of +0.20%. Regarding short-term risk, PHBI is more volatile compared to DMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HTSUF has a market cap of 2.1B. Regarding current trading prices, PHBI is priced at $0.00, while HTSUF trades at $28.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HTSUF's P/E ratio is 14.19. In terms of profitability, PHBI's ROE is +0.09%, compared to HTSUF's ROE of +0.05%. Regarding short-term risk, PHBI is more volatile compared to HTSUF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LJUIF has a market cap of 2.1B. Regarding current trading prices, PHBI is priced at $0.00, while LJUIF trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LJUIF's P/E ratio is 13.97. In terms of profitability, PHBI's ROE is +0.09%, compared to LJUIF's ROE of +0.19%. Regarding short-term risk, PHBI is more volatile compared to LJUIF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LBTSF has a market cap of 1.9B. Regarding current trading prices, PHBI is priced at $0.00, while LBTSF trades at $9.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LBTSF's P/E ratio is 150.17. In terms of profitability, PHBI's ROE is +0.09%, compared to LBTSF's ROE of +0.01%. Regarding short-term risk, PHBI is more volatile compared to LBTSF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NPNKF has a market cap of 1.7B. Regarding current trading prices, PHBI is priced at $0.00, while NPNKF trades at $25.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NPNKF's P/E ratio is 7.55. In terms of profitability, PHBI's ROE is +0.09%, compared to NPNKF's ROE of +0.09%. Regarding short-term risk, PHBI is more volatile compared to NPNKF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NPPNY has a market cap of 1.7B. Regarding current trading prices, PHBI is priced at $0.00, while NPPNY trades at $6.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NPPNY's P/E ratio is 7.36. In terms of profitability, PHBI's ROE is +0.09%, compared to NPPNY's ROE of +0.09%. Regarding short-term risk, PHBI is more volatile compared to NPPNY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SMDPY has a market cap of 1.6B. Regarding current trading prices, PHBI is priced at $0.00, while SMDPY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SMDPY's P/E ratio is 9.76. In terms of profitability, PHBI's ROE is +0.09%, compared to SMDPY's ROE of -1.44%. Regarding short-term risk, PHBI is more volatile compared to SMDPY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, PHBI is priced at $0.00, while MITPF trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas MITPF's P/E ratio is -10.81. In terms of profitability, PHBI's ROE is +0.09%, compared to MITPF's ROE of +4.92%. Regarding short-term risk, PHBI is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SHEZF has a market cap of 1.6B. Regarding current trading prices, PHBI is priced at $0.00, while SHEZF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, PHBI's ROE is +0.09%, compared to SHEZF's ROE of +0.05%. Regarding short-term risk, PHBI is less volatile compared to SHEZF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, PHBI is priced at $0.00, while KARBF trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas KARBF's P/E ratio is 262.50. In terms of profitability, PHBI's ROE is +0.09%, compared to KARBF's ROE of N/A. Regarding short-term risk, PHBI is more volatile compared to KARBF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, EVOTF has a market cap of 1.5B. Regarding current trading prices, PHBI is priced at $0.00, while EVOTF trades at $8.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas EVOTF's P/E ratio is -7.52. In terms of profitability, PHBI's ROE is +0.09%, compared to EVOTF's ROE of -0.22%. Regarding short-term risk, PHBI is less volatile compared to EVOTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, YIHCF has a market cap of 1.5B. Regarding current trading prices, PHBI is priced at $0.00, while YIHCF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, PHBI's ROE is +0.09%, compared to YIHCF's ROE of +0.19%. Regarding short-term risk, PHBI is more volatile compared to YIHCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ARSUF has a market cap of 1.5B. Regarding current trading prices, PHBI is priced at $0.00, while ARSUF trades at $20.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ARSUF's P/E ratio is 18.05. In terms of profitability, PHBI's ROE is +0.09%, compared to ARSUF's ROE of +0.16%. Regarding short-term risk, PHBI is more volatile compared to ARSUF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CHIZF has a market cap of 1.2B. Regarding current trading prices, PHBI is priced at $0.00, while CHIZF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CHIZF's P/E ratio is 12.00. In terms of profitability, PHBI's ROE is +0.09%, compared to CHIZF's ROE of +0.04%. Regarding short-term risk, PHBI is less volatile compared to CHIZF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, GTBIF has a market cap of 1.2B. Regarding current trading prices, PHBI is priced at $0.00, while GTBIF trades at $5.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas GTBIF's P/E ratio is 24.19. In terms of profitability, PHBI's ROE is +0.09%, compared to GTBIF's ROE of +0.03%. Regarding short-term risk, PHBI is more volatile compared to GTBIF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, KSPHF has a market cap of 1.2B. Regarding current trading prices, PHBI is priced at $0.00, while KSPHF trades at $27.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas KSPHF's P/E ratio is 14.35. In terms of profitability, PHBI's ROE is +0.09%, compared to KSPHF's ROE of +0.05%. Regarding short-term risk, PHBI is less volatile compared to KSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SWGHF has a market cap of 1.1B. Regarding current trading prices, PHBI is priced at $0.00, while SWGHF trades at $11.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, PHBI's ROE is +0.09%, compared to SWGHF's ROE of +0.10%. Regarding short-term risk, PHBI is more volatile compared to SWGHF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, PHBI is priced at $0.00, while GNMLF trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas GNMLF's P/E ratio is 10.36. In terms of profitability, PHBI's ROE is +0.09%, compared to GNMLF's ROE of +0.12%. Regarding short-term risk, PHBI is more volatile compared to GNMLF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CASBF has a market cap of 985.6M. Regarding current trading prices, PHBI is priced at $0.00, while CASBF trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CASBF's P/E ratio is -15.24. In terms of profitability, PHBI's ROE is +0.09%, compared to CASBF's ROE of -0.14%. Regarding short-term risk, PHBI is less volatile compared to CASBF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, KKPCF has a market cap of 980.3M. Regarding current trading prices, PHBI is priced at $0.00, while KKPCF trades at $26.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas KKPCF's P/E ratio is 10.54. In terms of profitability, PHBI's ROE is +0.09%, compared to KKPCF's ROE of +0.04%. Regarding short-term risk, PHBI is more volatile compared to KKPCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SHPHF has a market cap of 924.4M. Regarding current trading prices, PHBI is priced at $0.00, while SHPHF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SHPHF's P/E ratio is -3.33. In terms of profitability, PHBI's ROE is +0.09%, compared to SHPHF's ROE of -0.01%. Regarding short-term risk, PHBI is less volatile compared to SHPHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, BIOGY has a market cap of 884.8M. Regarding current trading prices, PHBI is priced at $0.00, while BIOGY trades at $8.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas BIOGY's P/E ratio is 28.07. In terms of profitability, PHBI's ROE is +0.09%, compared to BIOGY's ROE of +0.18%. Regarding short-term risk, PHBI is more volatile compared to BIOGY. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NRXCF has a market cap of 846.2M. Regarding current trading prices, PHBI is priced at $0.00, while NRXCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NRXCF's P/E ratio is -0.22. In terms of profitability, PHBI's ROE is +0.09%, compared to NRXCF's ROE of +2.32%. Regarding short-term risk, PHBI is more volatile compared to NRXCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, PHBI is priced at $0.00, while TWAPF trades at $16.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TWAPF's P/E ratio is 6.33. In terms of profitability, PHBI's ROE is +0.09%, compared to TWAPF's ROE of +0.09%. Regarding short-term risk, PHBI is less volatile compared to TWAPF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CSWYF has a market cap of 815.8M. Regarding current trading prices, PHBI is priced at $0.00, while CSWYF trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CSWYF's P/E ratio is 5.14. In terms of profitability, PHBI's ROE is +0.09%, compared to CSWYF's ROE of +0.07%. Regarding short-term risk, PHBI is more volatile compared to CSWYF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, ELTP has a market cap of 717.3M. Regarding current trading prices, PHBI is priced at $0.00, while ELTP trades at $0.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas ELTP's P/E ratio is -33.57. In terms of profitability, PHBI's ROE is +0.09%, compared to ELTP's ROE of -0.36%. Regarding short-term risk, PHBI is more volatile compared to ELTP. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NIKA has a market cap of 708.2M. Regarding current trading prices, PHBI is priced at $0.00, while NIKA trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NIKA's P/E ratio is N/A. In terms of profitability, PHBI's ROE is +0.09%, compared to NIKA's ROE of +0.39%. Regarding short-term risk, PHBI is more volatile compared to NIKA. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TCNNF has a market cap of 707M. Regarding current trading prices, PHBI is priced at $0.00, while TCNNF trades at $3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TCNNF's P/E ratio is -4.68. In terms of profitability, PHBI's ROE is +0.09%, compared to TCNNF's ROE of -0.13%. Regarding short-term risk, PHBI is more volatile compared to TCNNF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, PHBI is priced at $0.00, while TRXPF trades at $24.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, PHBI's ROE is +0.09%, compared to TRXPF's ROE of +0.04%. Regarding short-term risk, PHBI is more volatile compared to TRXPF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SWDCF has a market cap of 679.3M. Regarding current trading prices, PHBI is priced at $0.00, while SWDCF trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SWDCF's P/E ratio is 70.83. In terms of profitability, PHBI's ROE is +0.09%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, PHBI is more volatile compared to SWDCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LVTTF has a market cap of 664.6M. Regarding current trading prices, PHBI is priced at $0.00, while LVTTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LVTTF's P/E ratio is -0.02. In terms of profitability, PHBI's ROE is +0.09%, compared to LVTTF's ROE of +0.00%. Regarding short-term risk, PHBI is less volatile compared to LVTTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CURLF has a market cap of 632.3M. Regarding current trading prices, PHBI is priced at $0.00, while CURLF trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CURLF's P/E ratio is -2.53. In terms of profitability, PHBI's ROE is +0.09%, compared to CURLF's ROE of -0.25%. Regarding short-term risk, PHBI is more volatile compared to CURLF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, BOIRF has a market cap of 622.4M. Regarding current trading prices, PHBI is priced at $0.00, while BOIRF trades at $35.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas BOIRF's P/E ratio is 25.25. In terms of profitability, PHBI's ROE is +0.09%, compared to BOIRF's ROE of +0.06%. Regarding short-term risk, PHBI is more volatile compared to BOIRF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, PHBI is priced at $0.00, while TRSSF trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, PHBI's ROE is +0.09%, compared to TRSSF's ROE of -0.32%. Regarding short-term risk, PHBI is less volatile compared to TRSSF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, MNFSF has a market cap of 566M. Regarding current trading prices, PHBI is priced at $0.00, while MNFSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas MNFSF's P/E ratio is -0.08. In terms of profitability, PHBI's ROE is +0.09%, compared to MNFSF's ROE of +16.59%. Regarding short-term risk, PHBI is less volatile compared to MNFSF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, SGFEF has a market cap of 536.8M. Regarding current trading prices, PHBI is priced at $0.00, while SGFEF trades at $102.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas SGFEF's P/E ratio is 22.83. In terms of profitability, PHBI's ROE is +0.09%, compared to SGFEF's ROE of +0.11%. Regarding short-term risk, PHBI is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, PHBI is priced at $0.00, while CCHWF trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, PHBI's ROE is +0.09%, compared to CCHWF's ROE of -7.05%. Regarding short-term risk, PHBI is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, AIHLF has a market cap of 507.8M. Regarding current trading prices, PHBI is priced at $0.00, while AIHLF trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas AIHLF's P/E ratio is 10.83. In terms of profitability, PHBI's ROE is +0.09%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, PHBI is less volatile compared to AIHLF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, PHBI is priced at $0.00, while PEXXF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, PHBI's ROE is +0.09%, compared to PEXXF's ROE of N/A. Regarding short-term risk, PHBI is more volatile compared to PEXXF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, KHTRF has a market cap of 443.1M. Regarding current trading prices, PHBI is priced at $0.00, while KHTRF trades at $4.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas KHTRF's P/E ratio is 63.54. In terms of profitability, PHBI's ROE is +0.09%, compared to KHTRF's ROE of +0.01%. Regarding short-term risk, PHBI is more volatile compared to KHTRF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, AGYTF has a market cap of 405.1M. Regarding current trading prices, PHBI is priced at $0.00, while AGYTF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas AGYTF's P/E ratio is -8.50. In terms of profitability, PHBI's ROE is +0.09%, compared to AGYTF's ROE of -2.67%. Regarding short-term risk, PHBI is less volatile compared to AGYTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LRDSF has a market cap of 379.3M. Regarding current trading prices, PHBI is priced at $0.00, while LRDSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LRDSF's P/E ratio is -0.03. In terms of profitability, PHBI's ROE is +0.09%, compared to LRDSF's ROE of +1.61%. Regarding short-term risk, PHBI is more volatile compared to LRDSF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, BHHKF has a market cap of 291M. Regarding current trading prices, PHBI is priced at $0.00, while BHHKF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas BHHKF's P/E ratio is -0.01. In terms of profitability, PHBI's ROE is +0.09%, compared to BHHKF's ROE of -1.94%. Regarding short-term risk, PHBI is less volatile compared to BHHKF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, PKBFF has a market cap of 289.4M. Regarding current trading prices, PHBI is priced at $0.00, while PKBFF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas PKBFF's P/E ratio is -0.00. In terms of profitability, PHBI's ROE is +0.09%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, PHBI is less volatile compared to PKBFF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, BHCCF has a market cap of 271.2M. Regarding current trading prices, PHBI is priced at $0.00, while BHCCF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, PHBI's ROE is +0.09%, compared to BHCCF's ROE of -0.18%. Regarding short-term risk, PHBI is more volatile compared to BHCCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, GLASF has a market cap of 262.5M. Regarding current trading prices, PHBI is priced at $0.00, while GLASF trades at $5.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas GLASF's P/E ratio is -57.17. In terms of profitability, PHBI's ROE is +0.09%, compared to GLASF's ROE of +0.00%. Regarding short-term risk, PHBI is more volatile compared to GLASF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CPHRF has a market cap of 246.2M. Regarding current trading prices, PHBI is priced at $0.00, while CPHRF trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CPHRF's P/E ratio is 26.69. In terms of profitability, PHBI's ROE is +0.09%, compared to CPHRF's ROE of +0.09%. Regarding short-term risk, PHBI is more volatile compared to CPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, PSIQ has a market cap of 232.4M. Regarding current trading prices, PHBI is priced at $0.00, while PSIQ trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas PSIQ's P/E ratio is N/A. In terms of profitability, PHBI's ROE is +0.09%, compared to PSIQ's ROE of -1.73%. Regarding short-term risk, PHBI is less volatile compared to PSIQ. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, PHBI is priced at $0.00, while PLNHF trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, PHBI's ROE is +0.09%, compared to PLNHF's ROE of -0.34%. Regarding short-term risk, PHBI is less volatile compared to PLNHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, VRNOF has a market cap of 179.9M. Regarding current trading prices, PHBI is priced at $0.00, while VRNOF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas VRNOF's P/E ratio is -0.50. In terms of profitability, PHBI's ROE is +0.09%, compared to VRNOF's ROE of -0.22%. Regarding short-term risk, PHBI is less volatile compared to VRNOF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CRLBF has a market cap of 177.1M. Regarding current trading prices, PHBI is priced at $0.00, while CRLBF trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CRLBF's P/E ratio is -2.18. In terms of profitability, PHBI's ROE is +0.09%, compared to CRLBF's ROE of -0.16%. Regarding short-term risk, PHBI is more volatile compared to CRLBF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, WLDFF has a market cap of 170.2M. Regarding current trading prices, PHBI is priced at $0.00, while WLDFF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas WLDFF's P/E ratio is N/A. In terms of profitability, PHBI's ROE is +0.09%, compared to WLDFF's ROE of -0.19%. Regarding short-term risk, PHBI is less volatile compared to WLDFF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CBSTF has a market cap of 161.1M. Regarding current trading prices, PHBI is priced at $0.00, while CBSTF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CBSTF's P/E ratio is -0.23. In terms of profitability, PHBI's ROE is +0.09%, compared to CBSTF's ROE of +10.11%. Regarding short-term risk, PHBI is less volatile compared to CBSTF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HUMDF has a market cap of 147.5M. Regarding current trading prices, PHBI is priced at $0.00, while HUMDF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HUMDF's P/E ratio is -3.75. In terms of profitability, PHBI's ROE is +0.09%, compared to HUMDF's ROE of +8.06%. Regarding short-term risk, PHBI is more volatile compared to HUMDF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, NWPN has a market cap of 134.5M. Regarding current trading prices, PHBI is priced at $0.00, while NWPN trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas NWPN's P/E ratio is -0.04. In terms of profitability, PHBI's ROE is +0.09%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, PHBI is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, PHCUF has a market cap of 131.9M. Regarding current trading prices, PHBI is priced at $0.00, while PHCUF trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas PHCUF's P/E ratio is 495.00. In terms of profitability, PHBI's ROE is +0.09%, compared to PHCUF's ROE of +0.00%. Regarding short-term risk, PHBI is less volatile compared to PHCUF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, PHBI is priced at $0.00, while COPHF trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas COPHF's P/E ratio is -0.02. In terms of profitability, PHBI's ROE is +0.09%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, PHBI is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, HLTRF has a market cap of 115.8M. Regarding current trading prices, PHBI is priced at $0.00, while HLTRF trades at $3.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas HLTRF's P/E ratio is -6.42. In terms of profitability, PHBI's ROE is +0.09%, compared to HLTRF's ROE of -0.24%. Regarding short-term risk, PHBI is more volatile compared to HLTRF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, LPCUF has a market cap of 110.8M. Regarding current trading prices, PHBI is priced at $0.00, while LPCUF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas LPCUF's P/E ratio is 18.82. In terms of profitability, PHBI's ROE is +0.09%, compared to LPCUF's ROE of +0.05%. Regarding short-term risk, PHBI is more volatile compared to LPCUF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.

PHBI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHBI stands at 730K. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, PHBI is priced at $0.00, while CNVCF trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHBI currently has a P/E ratio of N/A, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, PHBI's ROE is +0.09%, compared to CNVCF's ROE of +9.56%. Regarding short-term risk, PHBI is more volatile compared to CNVCF. This indicates potentially higher risk in terms of short-term price fluctuations for PHBI.